Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Corcept Therapeutics Stock Fell as Much as 18.5% Today

By Maxx Chatsko – Updated Apr 22, 2019 at 9:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An investigative report is shining light on some very serious questions about the company. Shareholders absolutely must read it.

What happened

Shares of Corcept Therapeutics (CORT 1.74%) fell over 18% today after the Southern Investigative Reporting Foundation (SIRF) published a report about it. The report criticized the $1.4 billion company for exploiting regulatory loopholes, charging patients an excessive price for its lone drug product, and touting evidence for the drug's effectiveness that -- according to SIRF -- doesn't exist. 

It's just the latest blow for Corcept Therapeutics. Wall Street was already worried that its only drug product, Korlym, approved to treat Cushing's Syndrome, would struggle to stave off encroaching generic competition. Now, analysts will have a number of other worries.

As of 3:15 p.m. EST on Friday, the stock had settled to a 12.1% loss.

Declining red lines drawn on a chalkboard.

Image source: Getty Images.

So what

It's important for investors to know that SIRF is an investigative reporting foundation covering various topics in the financial sector. The board of directors includes well-known journalists such as William Cohan, the author of Money and Power, and Bethany McLean, who exposed fraud at Enron. The report published today about Corcept Therapeutics is not a short-seller report -- it's real journalism.

The SIRF report laid out a detailed case questioning the effectiveness of Korlym, including a regulatory rejection in Europe that went unanswered by Corcept for "strategic business reasons." The report also questioned the drug's safety, citing 37 deaths in the first nine months of 2018 reported to the Food and Drug Administration's adverse-events reporting system. It has been linked to 103 patient deaths since 2012.

Now what

Shareholders of Corcept Therapeutics, or any investors thinking that today's drop might be a buying opportunity, simply must read the investigative report. It sheds light on a host of very serious issues at the company that will need to be addressed by management. Whether or not the report leads to action from regulatory bodies such as the FDA or the Securities and Exchange Commission remains to be seen, but it is enough of a red flag to steer investors away from the stock.

Check out the latest Corcept Therapeutics earnings call transcript.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Corcept Therapeutics Stock Quote
Corcept Therapeutics
$26.84 (1.74%) $0.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.